Integrated Bioinformatics analysis and clinical validation reveals that high expression of mucin 1 in intrahepatic cholangiocarcinoma predicts recurrence after curative resection

Chen,Fei-Yu; Zhou,Cheng; Zhang,Xiang-Yu; Zhou,Kai-Qian; Peng,Yuan-Fei; Yu,Lei; Fan,Jia; Zhou,Jian; Hu,Jie; Wang,Zheng

doi:10.3892/etm.2020.9178

Integrated Bioinformatics analysis and clinical validation reveals that high expression of mucin 1 in intrahepatic cholangiocarcinoma predicts recurrence after curative resection

Authors:
- Fei-Yu Chen
- Cheng Zhou
- Xiang-Yu Zhang
- Kai-Qian Zhou
- Yuan-Fei Peng
- Lei Yu
- Jia Fan
- Jian Zhou
- Jie Hu
- Zheng Wang
View Affiliations

Affiliations: Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Fudan University, Ministry of Education, Shanghai 200032, P.R. China
Published online on: September 3, 2020 https://doi.org/10.3892/etm.2020.9178
Article Number: 50
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Intrahepatic cholangiocarcinoma (ICC) is a cancer type with high malignancy and a current lack of biomarkers to predict recurrence. In the present study, to identify potential biomarkers, five ICC datasets from the Gene Expression Omnibus database were analyzed to construct initial datasets by using a robust rank aggregation approach. A total of 19 upregulated genes were identified in the initial datasets. The genes identified were then further analysed using data from The Cancer Genome Atlas. Only mucin 1 (MUC1) exhibited significance regarding differential expression and survival prediction. Finally, the expression levels of MUC1 were assessed using reverse transcription‑quantitative PCR in 61 pairs of ICC tumor and matched non‑cancerous samples. The expression of MUC1 was significantly elevated in ICC tissues compared with that in matched non‑cancerous counterparts (P=0.001). Patients with high MUC1 expression levels had significantly shorter overall survival (OS, P=0.009) and recurrence‑free survival (RFS, P=0.012). MUC1 was identified as an independent prognostic factor for OS [hazard ratio (HR)=2.364, 95%CI: 1.214‑4.485; P=0.023] and RFS (HR=2.552 95%CI: 1.294‑5.032; P=0.007) in the multivariate analysis. Using receiver operating characteristic analysis, a co‑index including MUC1 had a high accuracy for predicting survival [MUC1 combined with serum levels of CEA and cancer antigen 19‑9, and lymph node metastasis, area under curve (AUC)=0.746, 95%CI: 0.620‑0.872] and recurrence (MUC1 combined with bile duct invasion and lymph node metastasis, AUC=0.729, 95%CI: 0.605‑854). In conclusion, MUC1 is highly expressed in ICC tissue and is a potential prognostic biomarker and therapeutic target for ICC.

View Figures

View References

1	Aljiffry M, Abdulelah A, Walsh M, Peltekian K, Alwayn I and Molinari M: Evidence-based approach to cholangiocarcinoma: A systematic review of the current literature. J Am Coll Surg. 208:134–147. 2009.PubMed/NCBI View Article : Google Scholar
2	Buettner S, van Vugt JL, IJzermans JN and Groot Koerkamp B: Intrahepatic cholangiocarcinoma: Current perspectives. Onco Targets Ther. 10:1131–1142. 2017.PubMed/NCBI View Article : Google Scholar
3	Schlinkert RT, Nagorney DM, Van Heerden JA and Adson MA: Intrahepatic cholangiocarcinoma: Clinical aspects, pathology and treatment. HPB Surg. 5:95–102. 1992.PubMed/NCBI View Article : Google Scholar
4	Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, D'Angelica M, DeMatteo RP, Fong Y, Schwartz L, et al: Intrahepatic cholangiocarcinoma: Rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 248:84–96. 2008.PubMed/NCBI View Article : Google Scholar
5	Dodson RM, Weiss MJ, Cosgrove D, Herman JM, Kamel I, Anders R, Geschwind JF and Pawlik TM: Intrahepatic cholangiocarcinoma: Management options and emerging therapies. J Am Coll Surg. 217:736–750.e4. 2013.PubMed/NCBI View Article : Google Scholar
6	Shaib YH, Davila JA, McGlynn K and El-Serag HB: Rising incidence of intrahepatic cholangiocarcinoma in the United States: A true increase? J Hepatol. 40:472–477. 2004.PubMed/NCBI View Article : Google Scholar
7	Yamashita Y, Taketomi A, Morita K, Fukuhara T, Ueda S, Sanefuji K, Iguchi T, Kayashima H, Sugimachi K and Maehara Y: The impact of surgical treatment and poor prognostic factors for patients with intrahepatic cholangiocarcinoma: Retrospective analysis of 60 patients. Anticancer Res. 28:2353–2359. 2008.PubMed/NCBI
8	Weber SM, Ribero D, O'Reilly EM, Kokudo N, Miyazaki M and Pawlik TM: Intrahepatic cholangiocarcinoma: Expert consensus statement. HPB (Oxford). 17:669–680. 2015.PubMed/NCBI View Article : Google Scholar
9	Popat K, McQueen K and Feeley TW: The global burden of cancer. Best Pract Res Clin Anaesthesiol. 27:399–408. 2013.PubMed/NCBI View Article : Google Scholar
10	Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM and Gores GJ: Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 60:1268–1289. 2014.PubMed/NCBI View Article : Google Scholar
11	Rao CV, Asch AS and Yamada HY: Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer. Carcinogenesis. 38:2–11. 2017.PubMed/NCBI View Article : Google Scholar
12	Rizvi S and Gores GJ: Emerging molecular therapeutic targets for cholangiocarcinoma. J Hepatol. 67:632–644. 2017.PubMed/NCBI View Article : Google Scholar
13	Rahnemai-Azar AA, Weisbrod A, Dillhoff M, Schmidt C and Pawlik TM: Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis. Surg Oncol. 26:125–137. 2017.PubMed/NCBI View Article : Google Scholar
14	Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schütz F, et al: Meta-analysis of gene expression profiles in breast cancer: Toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 10(R65)2008.PubMed/NCBI View Article : Google Scholar
15	Võsa U, Kolde R, Vilo J, Metspalu A and Annilo T: Comprehensive meta-analysis of microRNA expression using a robust rank aggregation approach. Methods Mol Biol. 1182:361–373. 2014.PubMed/NCBI View Article : Google Scholar
16	Kolde R, Laur S, Adler P and Vilo J: Robust rank aggregation for gene list integration and meta-analysis. Bioinformatics. 28:573–580. 2012.PubMed/NCBI View Article : Google Scholar
17	Edgar R, Domrachev M and Lash AE: Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30:207–210. 2002.PubMed/NCBI View Article : Google Scholar
18	Smyth GK: In Bioinformatics and Computational Biology Solutions Using R and Bioconductor (Springer-Verlag, New York), Statistics for Biology and Health, pp397-420, 2005.
19	McCarthy DJ, Chen Y and Smyth GK: Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res. 40:4288–4297. 2012.PubMed/NCBI View Article : Google Scholar
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
21	Amin MB: AJCC Cancer Staging Manual, 8th edition.
22	Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, Nellore V, Kongpetch S, Ng AWT, Ng LM, et al: Whole-Genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 7:1116–1135. 2017.PubMed/NCBI View Article : Google Scholar
23	Chaisaingmongkol J, Budhu A, Dang H, Rabibhadana S, Pupacdi B, Kwon SM, Forgues M, Pomyen Y, Bhudhisawasdi V, Lertprasertsuke N, et al: Common molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell. 32:57–70.e3. 2017.PubMed/NCBI View Article : Google Scholar
24	Murakami Y, Kubo S, Tamori A, Itami S, Kawamura E, Iwaisako K, Ikeda K, Kawada N, Ochiya T and Taguchi YH: Comprehensive analysis of transcriptome and metabolome analysis in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. Sci Rep. 5(16294)2015.PubMed/NCBI View Article : Google Scholar
25	Oishi N, Kumar MR, Roessler S, Ji J, Forgues M, Budhu A, Zhao X, Andersen JB, Ye QH, Jia HL, et al: Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology. 56:1792–1803. 2012.PubMed/NCBI View Article : Google Scholar
26	Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR, et al: Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 142:1021–1031.e15. 2012.PubMed/NCBI View Article : Google Scholar
27	Guro H, Kim JW, Choi Y, Cho JY, Yoon YS and Han HS: Multidisciplinary management of intrahepatic cholangiocarcinoma: Current approaches. Surg Oncol. 26:146–152. 2017.PubMed/NCBI View Article : Google Scholar
28	Kaczynski J, Hansson G and Wallerstedt S: Incidence, etiologic aspects and clinicopathologic features in intrahepatic cholangiocellular carcinoma-a study of 51 cases from a low-endemicity area. Acta Oncol. 37:77–83. 1998.PubMed/NCBI View Article : Google Scholar
29	Brayman M, Thathiah A and Carson DD: MUC1: A multifunctional cell surface component of reproductive tissue epithelia. Reprod Biol Endocrinol. 2(4)2004.PubMed/NCBI View Article : Google Scholar
30	Aplin JD, Hey NA and Li TC: MUC1 as a cell surface and secretory component of endometrial epithelium: Reduced levels in recurrent miscarriage. Am J Reprod Immunol. 35:261–266. 1996.PubMed/NCBI View Article : Google Scholar
31	Wei X, Xu H and Kufe D: Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell. 7:167–178. 2005.PubMed/NCBI View Article : Google Scholar
32	Roy LD, Sahraei M, Subramani DB, Besmer D, Nath S, Tinder TL, Bajaj E, Shanmugam K, Lee YY, Hwang SI, et al: MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene. 30:1449–1459. 2011.PubMed/NCBI View Article : Google Scholar
33	Higashi M, Yonezawa S, Ho JJ, Tanaka S, Irimura T, Kim YS and Sato E: Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: Its relationship with a new morphological classification of cholangiocarcinoma. Hepatology. 30:1347–1355. 1999.PubMed/NCBI View Article : Google Scholar
34	Park SY, Roh SJ, Kim YN, Kim SZ, Park HS, Jang KY, Chung MJ, Kang MJ, Lee DG and Moon WS: Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: Prognostic impact. Oncol Rep. 22:649–657. 2009.PubMed/NCBI View Article : Google Scholar
35	Ruys AT, Groot Koerkamp B, Wiggers JK, Klümpen HJ, ten Kate FJ and van Gulik TM: Prognostic biomarkers in patients with resected cholangiocarcinoma: A systematic review and meta-analysis. Ann Surg Oncol. 21:487–500. 2014.PubMed/NCBI View Article : Google Scholar
36	Pillai K, Pourgholami MH, Chua TC and Morris DL: MUC1 as a potential target in anticancer therapies. Am J Clin Oncol. 38:108–118. 2015.PubMed/NCBI View Article : Google Scholar
37	Sasaki M, Nakanuma Y and Kim YS: Characterization of apomucin expression in intrahepatic cholangiocarcinomas and their precursor lesions: An immunohistochemical study. Hepatology. 24:1074–1078. 1996.PubMed/NCBI View Article : Google Scholar
38	Lakshminarayanan V, Thompson P, Wolfert MA, Buskas T, Bradley JM, Pathangey LB, Madsen CS, Cohen PA, Gendler SJ and Boons GJ: Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc Natl Acad Sci USA. 109:261–266. 2012.PubMed/NCBI View Article : Google Scholar
39	Nemunaitis J, Bedell C, Klucher K, Vo A and Whiting S: Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in patients with advanced cancer. J Immunother Cancer. 1 (Suppl 1)(P240)2013.